Ipsen and bioMérieux have entered into a global collaboration around theranostics (personalized diagnostic medicine), with a focus on hormone-dependent cancers. The two companies will leverage their expertise and resources to develop a personalized approach to medicine based on Ipsen’s portfolio of compounds and bioMérieux’s diagnostic tests.

The companies will jointly identify programs for the co-development of a therapeutic and a companion diagnostic test, particularly in the prevention and treatment of prostate and breast cancers, neuro-endocrine tumors (NETs) and pituitary tumors.

“We are very pleased to build this partnership with Ipsen, which has developed over the years a significant scientific and medical expertise. Our goal is to reinforce personalized medicine and contribute through this partnership to the novel paradigm in medicine, which is increasingly “patient-driven” rather than “disease-driven”,” said Prof. Christian Bréchot, vice president of Institut Mérieux, in charge of medical and scientific affairs.